The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration

Part of paid clinical trials in Rochester, New York.

Sponsor
University of Rochester
Study ID
NCT06319872
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Oral disulfiram — DRUG
    250 mg/day

Study Details

Oral disulfiram (Antabuse®) has been shown to improve image-forming vision in animal models with retinal degeneration due to its ability to decrease Retinoic Acid synthesis and consequently reduce hyperactivity in the inner retina. The investigator will aim to evaluate the impact of oral disulfiram on the vision of patients with retinal degeneration who are being treated with the drug in the management of their concurrent alcohol use disorder.

Key Dates

Start date
May 19, 2025
Status verified
May 2025
Primary completion
May 19, 2029
Completion
May 19, 2029

Study Design

Enrollment
15 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: All participants
    Participants will receive either drug or placebo for 180 days.

Primary Outcome Measure

mean change in Best Corrected Visual Acuity (BCVA) score assessed by ETDRS [ Time Frame: baseline to day 180 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Flaum Eye Institute, University of Rochester Medical CenterRochesterNew York14642
Evan Burr
[email protected]
585- 275-5234
Alex Levin, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Rochester, NY

By condition
Age-related macular degenerationSubstance use disorder
By specialty
OphthalmologyRetinaBehavioral healthAddiction medicine
By research site
Flaum Eye Institute, University of Rochester Medical Center· Rochester, NY

Related Studies